The Amylin case is a 2-day trial to determine the validity of a "poison put" takeover defense that would protect Amylin's board of directors from being replaced. Carl Icahn, who owns 9.4% of Amylin, and the hedge fund Eastbourne Capital, which ow...
Settlement hearing. The court previously held a hearing on a on motion for a preliminary injunction in suit seeking to block acquisition of Genentech Inc (NYSE) by Roche Holdings Inc. View Proceeding
Suit alleging that various pharmaceutical companies failed to disclose the potential side effects of Fen Phen, a popular diet medication, which included primary hypertension and valve disease. View Proceeding
Suit brought by the state's attorney general against Pfizer's Pharmacia unit and other pharmaceutical manufacturers alleging they overcharged the state's Medicaid system. Litigation over "average wholesale prices" for medication charged to state M...
The plaintiffs trade secret misappropriation claims arise out of Coronary Artery Bypass Graft (CABG) clinical drug trials for Bextra, a second generation COX-2 inhibitor.According to plaintiff non-profit Ischemia Research & Education Foundati... View Proceeding
Hearing on motion for partial summary judgment and partial judgment on the pleadings. Mangano, plaintiff, co-founded PeriCor Therapeutics, defendant, in 2004 and owns 45% of the biotech company, alleging breach of a voting trust agreement. PeriCor... View Proceeding
